Category Archives: Public View
All pages are restricted to logged in viewers except those with Category “Public View”
D.C. UPDATE – November 10, 2022
D.C. UPDATE – November 4, 2022
D.C. UPDATE – October 27, 2022
TECHNICAL BRIEF: CENSUS OF OPIOID TREATMENT PROGRAMS
In order to capture current patient census data for people being treated for opioid use disorder in OTPs, the National Association of State Alcohol and Drug Abuse Directors (NASADAD) in partnership with the American Association for the Treatment of Opioid Dependence (AATOD), developed a census survey of all patients enrolled in treatment as of January 1, 2021, in Substance Abuse and Mental Health Service Administration (SAMHSA) certified OTPs in the United States (U.S.). The project was supported by the SAMHSA-funded Opioid Response Network (ORN).
The purpose of the survey was to determine the number of patients receiving medications for opioid use disorders (MOUD) in OTPs, the types of federally approved medications being used by patients in treatment, and the specific formulations of medication used among the patient population.
This is the first time that such information is being made available to federal and state agencies that have jurisdiction in this area in addition to the general public.
At the time of the census, 1,826 OTPs were listed in the SAMHSA OTP directory. A total of 1,547 OTPs across the country completed the census survey, reflecting an 85% response rate. The full report indicates the medication breakdown for 512,224 patients. Of the 512,224 patients in OTPs who reported using MOUDs, 476,763 reported using methadone, 33,473 reported buprenorphine, and the remaining 1,988 reported using naltrexone. In addition to the most common MOUDs being used, the census captured formulation data from 510,557 patients including the most common formulation types, the number of patients using each formulation, and regional differences between formulation use.
Through this census, NASADAD and AATOD have captured crucial and actionable data to better understand treatment demand and demand for specific medications in OTPs. This report lays important groundwork to examine future demand and service issues in OTPs.
Contact:
Melanie Whitter
Deputy Executive Director and Director, Research and Program Applications
National Association of State Alcohol and Drug Abuse Directors, Inc.
mwhitter@nasadad.org
(202) 292-4873
Mark W. Parrino
President
American Association for the Treatment of Opioid Dependence (AATOD)
mark.parrino@aatod.org
(212) 566-5555 Ext: 200
Reauthorization of the State Opioid Response (SOR) Grant Program
The State Opioid Response (SOR) grant program, housed within the Substance Abuse and Mental Health Services (SAMHSA), is a federal grant program designed to address the “opioid overdose crisis by providing resources to states and territories for increasing access to FDA-approved medications for the treatment of opioid use disorder (MOUD), and for supporting the continuum of prevention, harm reduction, treatment, and recovery support services for opioid use disorder (OUD) and other concurrent substance use disorders (SAMHSA, 2022).”
The National Association of State Alcohol and Drug Abuse Directors (NASADAD) serves as the voice of State alcohol and drug agencies in Washington, D.C. NASADAD’s members are the State Single Agencies (SSAs) responsible for applying, receiving, and distributing SOR funds to programs and providers. The SOR grant program is currently up for reauthorization. As a result, NASADAD has developed an overview of key provisions in legislation in the the House of Representatives and Senate to reauthorize the program.
For more information about how States are using SOR funds, please visit the IMPACT OF STATE TARGETED RESPONSE & STATE OPIOID RESPONSE GRANTS.
This fact sheet is a “living document” and will continue to be updated as legislation progresses through Congress. Please reach out to Lacy Adams (Ladams@nasadad.org) with any questions.
Frequently Asked Questions (FAQs) About President Joe Biden’s Proclamation to Pardon Simple Marijuana Offenses
On October 6, 2022, President Joe Biden issued A Proclamation on Granting Pardon for the Offense of Simple Possession of Marijuana. The Proclamation set in motion a pathway to pardon all individuals with simple possession of marijuana offenses in violation of the Controlled Substances Act (U.S.C.844) or in violation of D.C. Code 48–904.01(d)(1). In response, NASADAD developed a fact sheet for State alcohol and drug agencies, Frequently Asked Questions (FAQs) About President Joe Biden’s Proclamation to Pardon Simple Marijuana Offenses, that explores answers to common questions around the timeline for pardons, what does receiving a presidential pardon entail, who does this proclamation apply to, and more.